DA Berry

1.1k total citations · 1 hit paper
9 papers, 841 citations indexed

About

DA Berry is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, DA Berry has authored 9 papers receiving a total of 841 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 7 papers in Cancer Research and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in DA Berry's work include Breast Cancer Treatment Studies (7 papers), Cancer Treatment and Pharmacology (5 papers) and Advanced Breast Cancer Therapies (3 papers). DA Berry is often cited by papers focused on Breast Cancer Treatment Studies (7 papers), Cancer Treatment and Pharmacology (5 papers) and Advanced Breast Cancer Therapies (3 papers). DA Berry collaborates with scholars based in United States. DA Berry's co-authors include P. D. Willson, Patrick L. McGeer, Alfred W. Kaszniak, L. Kirby, Frederick J. Kogan, C. Cirrincione, Larry Norton, Eric P. Winer, Maria Theodoulou and H. B. Muss and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Cancer Research.

In The Last Decade

DA Berry

8 papers receiving 812 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical trial of indomethacin in Alzheimer's disease

1993 804 citations L. Kirby, DA Berry et al. Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
DA Berry United States	4	512	325	306	167	139	9	841
Boris Decourt United States	17	487 1.0×	231 0.7×	183 0.6×	323 1.9×	125 0.9×	48	1.0k
J. Jacob Kulstad United States	8	740 1.4×	249 0.8×	151 0.5×	335 2.0×	87 0.6×	10	1.1k
Inelia Morales Chile	6	569 1.1×	360 1.1×	204 0.7×	256 1.5×	166 1.2×	10	959
David Beaulieu‐Abdelahad United States	19	424 0.8×	213 0.7×	205 0.7×	408 2.4×	58 0.4×	31	1.0k
Katherine R. Sadleir United States	12	850 1.7×	255 0.8×	256 0.8×	488 2.9×	106 0.8×	21	1.3k
Gunilla Osswald Sweden	8	711 1.4×	172 0.5×	337 1.1×	326 2.0×	105 0.8×	12	978
Danira Toral-Ríos Mexico	11	475 0.9×	268 0.8×	133 0.4×	308 1.8×	112 0.8×	14	861
Diana Franco-Bocanegra Mexico	9	452 0.9×	363 1.1×	104 0.3×	239 1.4×	118 0.8×	11	810
Paul Acton United States	8	605 1.2×	151 0.5×	177 0.6×	243 1.5×	49 0.4×	9	753

Countries citing papers authored by DA Berry

Since Specialization

Citations

This map shows the geographic impact of DA Berry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by DA Berry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites DA Berry more than expected).

Fields of papers citing papers by DA Berry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by DA Berry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by DA Berry. The network helps show where DA Berry may publish in the future.

Co-authorship network of co-authors of DA Berry

This figure shows the co-authorship network connecting the top 25 collaborators of DA Berry. A scholar is included among the top collaborators of DA Berry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with DA Berry. DA Berry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Krop, IE, Maki Tanioka, Joseph F. Parker, et al.. (2018). Abstract GS3-02: Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab. Cancer Research. 78(4_Supplement). GS3–2. 4 indexed citations

2.

Paoloni, Marco, et al.. (2017). Abstract P2-11-02: A longitudinal look at toxicity management within a platform trial: Lessons from the I-SPY 2 TRIAL. Cancer Research. 77(4_Supplement). P2–11. 2 indexed citations

3.

Yau, Christopher, Jiapeng Deng, Lamorna Brown Swigart, et al.. (2016). Abstract P3-07-48: Prediction of complete pathologic response to veliparib/carboplatin plus standard neoadjuvant therapy in HER2 negative breast cancer: Exploratory protein pathway marker results from the I-SPY 2 trial. Cancer Research. 76(4_Supplement). P3–7. 2 indexed citations

4.

Shulman, L., C. Cirrincione, DA Berry, et al.. (2010). Abstract S6-3: Four vs 6 Cycles of Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes: CALGB 40101 — A 2x2 Factorial Phase III Trial: First Results Comparing 4 vs 6 Cycles of Therapy. Cancer Research. 70(24_Supplement). S6–3. 4 indexed citations

5.

Berry, DA, et al.. (2009). High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 6 randomized metastatic breast cancer trials.. Cancer Research. 69(2_Supplement). 6113–6113. 3 indexed citations

6.

Muss, H. B., DA Berry, C. Cirrincione, et al.. (2008). Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907. Journal of Clinical Oncology. 26(15_suppl). 507–507. 19 indexed citations

7.

Muss, H. B., DA Berry, C. Cirrincione, et al.. (2006). Toxicity of older and younger patients (pts) treated (Rx) with intensive adjuvant chemotherapy (Cx) for node-positive (N+) breast cancer (BC): The CALGB experience. Journal of Clinical Oncology. 24(18_suppl). 559–559.

8.

Buchholz, Thomas A., DA Berry, Eric A. Strom, et al.. (2003). Her2-Neu overexpression does not increase the risk of local-regional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiation. International Journal of Radiation Oncology*Biology*Physics. 57(2). S201–S201. 3 indexed citations

9.

Kirby, L., DA Berry, Patrick L. McGeer, et al.. (1993). Clinical trial of indomethacin in Alzheimer's disease. Neurology. 43(8). 1609–1609. 804 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact